Industry News
'Achilles heel' of tumour cells discovered
A study has shown that fast-growing cancer cells are sensitive towards imbalances in the metabolism of nucleotides, the building blocks of DNA - a vulnerability that can be exploited for a novel anti-tumour therapeutic approach. [ + ]
The dangers of degrading plastic
Australian researchers are using the tracer principle to confirm the presence of plastics and chemicals in the food chain. The research began when Professor Richard Banati and Dr Jennifer Laver found elements in the feathers of seabirds which were similar to those found in plastics in its gut. [ + ]
Insights into plant immunity
A chemical has been identified that provides broad spectrum disease protection in plants. [ + ]
Victoria Prizes and Victoria Fellowships
Nominations are open for two Victoria Prizes for Science & Innovation and the 2014 Victoria Fellowships. [ + ]
STA to distribute Iluvien in A/NZ
Specialised Therapeutics Australia has become the exclusive distributor in ANZ for Iluvien, a DMO treatment being commercialised by Alimera Sciences under licence from pSivida (ASX:PVA). [ + ]
Lonza certification and committee changes
Lonza Bioscience Singapore has received cGMP certification from the Singapore Health Sciences Authority (HSA) for its cell-therapy manufacturing facility, while Lonza Group has announced changes in the composition of its executive committee (EC). [ + ]
Honey researcher receives USC Chancellor's Medal
Environmental scientist Daniel Meloncelli has been awarded a University of the Sunshine Coast (USC) Chancellor's Medal. It was one of only three Chancellor's Medals presented at USC's recent graduation ceremonies, awarded to outstanding graduates who have contributed to the university or wider community and achieved a high academic level during their studies. [ + ]
BioBusiness Asia Conference calls for presenting proposals
The 2014 BioBusiness Asia Conference, this year combined with BioTaiwan Exhibition 2014 to enlarge the partnering candidate pool, is calling for proposals from companies interested in presenting. [ + ]
Prima starts recruiting for ovarian cancer trial
Prima BioMed (ASX:PRR) has signed up the first patient for CAN-004, its phase II trial of therapy candidate CVac in epithelial ovarian cancer. [ + ]
Haplomic Technologies nabs EU, US patents
Haplomic Technologies has picked up patents in the EU and the US for its core IP, which covers genetic sequencing technologies based on haplotypes. [ + ]
US excipients market forecast to rise
US research firm The Freedonia Group has released the report 'Excipients', an industry study showcasing trends and forecasts in the pharmaceutical excipients market. The study also analyses market environment factors, evaluates company market share and profiles 47 US industry competitors. [ + ]
New genes found on Y chromosomes
A comparison of Y chromosome sequences across various mammals has revealed new gene repertoires for the major groups. [ + ]
Cell Therapies names new CEO
Cell Therapies has selected Dr Tim Oldham to become its new CEO to help drive the company's South-East Asian growth strategy. [ + ]
Successful antibody screening study
Therapeutic antibody supplier MorphoSys and technology company Biametrics will continue their collaboration in the area of high-throughput antibody screening following a successful feasibility study. [ + ]
Phosphagenics completes enrolment in acne trial
Phosphagenics has completed enrolment for a phase II trial of an acne treatment candidate that uses its TPM transdermal drug delivery technology. [ + ]
